New hope in global fight against antibiotic resistant superbugs
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler will meet with investors during the JP Morgan Healthcare conference, which will run virtually this year from 11th-15th January 2021. Dr Stamler, who was recently appointed CEO of Alterity, is presenting at the HC Wainwright BioConnect and Biotech Showcase events. Both ...
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development. Mr Geoffrey Kempler, who founded ...
New commercial opportunity for PBT2 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs. Under the licence, Alterity has secured the worldwide exclusive ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO and Chairman Mr Geoffrey Kempler will present to investors at the Finance News Network event today at 12.55pm. The event is partnered with stockbroking firm Shaw and Partners and is expected to be attended by trustees of self- managed superannuation funds, high net-worth investors, ...
AGM 2020 Presentation
Chairman’s Address to Shareholders 2020 AGM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-house discovery research and is central to Alterity’s next generation drug development portfolio focussed on neurodegenerative diseases. ...
Alterity Therapeutics today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States. BioMUSE is a natural history study that aims to track the progression of patients with MSA, a Parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical ...
Receive news from Alterity Therapeutics
